The Australian Technical Advisory Group on Immunisation (ATAGI) has provided a recommendation that the Moderna bivalent vaccine can be used as an alternative vaccine for any booster dose in people aged 18 years or older, according to the current ATAGI recommendations for booster doses. On 29 August, the TGA provisionally approved Moderna's bivalent COVID-19 vaccine for use as a booster dose in adults 18 years and over, and this vaccine has been available since 10 October 2022. On 21 April 2023, the TGA approved Moderna Australia’s application to transition its COVID-19 vaccine, SPIKEVAX (elasomeran), from provisional to full registration. 19 July 2022 (primary course – for children 6 months and over) (6 month to 5 year formulation)ģ0 August 2022 (booster – for 18 years and over) (bivalent original/Omicron BA.1 formulation).17 February 2022 (primary course - for 6 years and over) (half the adult dose).7 December 2021 (booster – for 18 years and over).3 September 2021 (primary course - for 12 years and over).9 August 2021 (primary course - for 18 years and over).The Therapeutic Good Administration (TGA) provisionally approved it for use in Australia on: Moderna is approved and available for use as a booster in people aged 18 years and over. Spikevax (Moderna) is approved and available for use as a primary course in people aged 6 months and over. Information on this page has been superseded by new ATAGI advice on the preferential use of bivalent COVID-19 vaccines for primary course and will be updated shortly.
0 Comments
Leave a Reply. |